Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

 Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

Shots:

  • MTPC to receive upfront, development & regulatory milestones and royalties on sales. Bausch Health to get exclusive WW rights to develop & commercialize MT-1303 (Ex-Japan & few other countries in Asia) in all fields (Ex. neurology, rheumatology and certain rare dermatology diseases)
  • Bausch plans to initiate the development of MTPC’s MT-1303 (amiselimod) in ulcerative colitis. MTPC will utilize the clinical data conducted by Bausch for regulatory approval and further commercialize it in Japan and certain other countries
  • MT-1303 (amiselimod) targets sphingosine-1-phosphate (S1P) receptor to retain lymphocytes sequestered in the lymph nodes and is evaluated in clinical studies for multiple sclerosis, psoriasis, Crohn’s disease and systemic lupus erythematosus across Europe & Japan

Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Financial Post

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post